Literature DB >> 18077165

Anti-Pneumocystis carinii and antiplasmodial activities of primaquine-derived imidazolidin-4-ones.

Nuno Vale1, Margaret S Collins, Jiri Gut, Ricardo Ferraz, Philip J Rosenthal, Melanie T Cushion, Rui Moreira, Paula Gomes.   

Abstract

A series of primaquine-derived imidazolidin-4-ones were screened for their in vitro activity against Pneumocystis carinii and Plasmodium falciparum W2 strain. Most compounds were active against P. carinii above 10 microg/mL and displayed slight to marked activity. The imidazolidin-4-ones most active against P. carinii were also those most active antiplasmodial agents, in the muM range. One of the tested imidazolidin-4-ones was slightly more active than the parent primaquine and may represent a lead compound for the development of novel anti-P. carinii 8-aminoquinolines with increased stability and resistance to metabolic inactivation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18077165     DOI: 10.1016/j.bmcl.2007.11.105

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  10 in total

1.  Pneumocystis carinii expresses an active Rtt109 histone acetyltransferase.

Authors:  Theodore J Kottom; Junhong Han; Zhiguo Zhang; Andrew H Limper
Journal:  Am J Respir Cell Mol Biol       Date:  2010-07-23       Impact factor: 6.914

2.  Synthesis and structure-activity relationships of carbohydrazides and 1,3,4-oxadiazole derivatives bearing an imidazolidine moiety against the yellow fever and dengue vector, Aedes aegypti.

Authors:  Fatih Tok; Bedia Kocyigit-Kaymakcioglu; Nurhayat Tabanca; Alden S Estep; Aaron D Gross; Werner J Geldenhuys; James J Becnel; Jeffrey R Bloomquist
Journal:  Pest Manag Sci       Date:  2017-10-23       Impact factor: 4.845

3.  Peptidomimetic and organometallic derivatives of primaquine active against Leishmania infantum.

Authors:  Sílvia Vale-Costa; Nuno Vale; Joana Matos; Ana Tomás; Rui Moreira; Paula Gomes; Maria Salomé Gomes
Journal:  Antimicrob Agents Chemother       Date:  2012-08-27       Impact factor: 5.191

4.  Electrospray ionization-ion trap mass spectrometry study of PQAAPro and PQProAA mimetic derivatives of the antimalarial primaquine.

Authors:  Nuno Vale; Joana Matos; Rui Moreira; Paula Gomes
Journal:  J Am Soc Mass Spectrom       Date:  2008-07-01       Impact factor: 3.109

5.  Imidazoquines as antimalarial and antipneumocystis agents.

Authors:  Nuno Vale; Miguel Prudêncio; Catarina A Marques; Margaret S Collins; Jiri Gut; Fátima Nogueira; Joana Matos; Philip J Rosenthal; Melanie T Cushion; Virgílio E do Rosário; Maria M Mota; Rui Moreira; Paula Gomes
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

6.  Crystal structure of ethyl 2-(4-chlorophenyl)-3-cyclopentyl-4-oxo-1-propyl-imidazolidine-5-carboxylate.

Authors:  Mohamed Ali Tabarki; Youssef Ben Smida; Abderrahmen Guesmi; Rafâa Besbes
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2015-08-22

Review 7.  Primaquine derivatives: Modifications of the terminal amino group.

Authors:  Branka Zorc; Ivana Perković; Kristina Pavić; Zrinka Rajić; Maja Beus
Journal:  Eur J Med Chem       Date:  2019-08-23       Impact factor: 6.514

8.  Synthesis, Biological Activity and In Silico Pharmacokinetic Prediction of a New 2-Thioxo-Imidazoldidin-4-One of Primaquine.

Authors:  Mariana Pereira; Guy Caljon; Maria João Gouveia; Louis Maes; Nuno Vale
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-27

9.  Enantioselective Interactions of Anti-Infective 8-Aminoquinoline Therapeutics with Human Monoamine Oxidases A and B.

Authors:  Narayan D Chaurasiya; Haining Liu; Robert J Doerksen; N P Dhammika Nanayakkara; Larry A Walker; Babu L Tekwani
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-22

10.  Chloroquine Analogues as Leads against Pneumocystis Lung Pathogens.

Authors:  Ana Gomes; Ricardo Ferraz; Lauren Ficker; Margaret S Collins; Cristina Prudêncio; Melanie T Cushion; Cátia Teixeira; Paula Gomes
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.